Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo
  • +14
  • Yajing Xing,
  • Weikai Guo,
  • Min Wu,
  • Jiuqing Xie,
  • Dongxia Huang,
  • Pan Hu,
  • Miaoran Zhou,
  • Qiansheng Zhang,
  • Peili wang,
  • Xin Wang,
  • Guixue Wang,
  • Huangan Wu,
  • Cili Zhou,
  • Yihua Chen,
  • Mingyao Liu,
  • Zhengfang Yi,
  • Zhenliang Sun
Yajing Xing
East China Normal University
Author Profile
Weikai Guo
East China Normal University
Author Profile
Min Wu
East China Normal University
Author Profile
Jiuqing Xie
East China Normal University
Author Profile
Dongxia Huang
East China Normal University
Author Profile
Pan Hu
East China Normal University
Author Profile
Miaoran Zhou
Shanghai University of Traditional Chinese Medicine
Author Profile
Qiansheng Zhang
East China Normal University
Author Profile
Peili wang
East China Normal University
Author Profile
Xin Wang
East China Normal University
Author Profile
Guixue Wang
Chongqing University
Author Profile
Huangan Wu
Shanghai University of Traditional Chinese Medicine
Author Profile
Cili Zhou
Shanghai University of Traditional Chinese Medicine
Author Profile
Yihua Chen
East China Normal University
Author Profile
Mingyao Liu
East China Normal University
Author Profile
Zhengfang Yi
East China Normal University

Corresponding Author:[email protected]

Author Profile
Zhenliang Sun
Shanghai University of Medicine and Health Sciences
Author Profile

Abstract

Background and Purpose: The transcription factor B cell lymphoma 6 (BCL6) is an oncogenic driver of diffuse large B cell lymphoma (DLBCL). Blocking the protein-protein interactions of BCL6 and its corepressors has been proposed as an effective approach for the treatment of DLBCL. However, BCL6 inhibitors with excellent drug-like properties are rare. Hence, the development of BCL6 inhibitors is worth pursuing. Experimental Approach: We screened our internal chemical library by luciferase reporter assay and Homogenous Time Resolved Fluorescence (HTRF) assay and a small molecule compound named WK500B was identified. The binding affinity between WK500B and BCL6 was evaluated by surface plasmon resonance (SPR) assay and the binding mode of WK500B and BCL6 was predicted by molecular docking. The function evaluation and anti-cancer activity of WK500B was detected by immunofluorescence assay, Real-Time Quantitative PCR, cell proliferation assay, cell cycle assay, cell apoptosis assay, enzyme-linked immunosorbent assay (ELISA) and animal models. Key Results: WK500B engaged BCL6 inside cells, blocked BCL6 repression complexes, reactivated BCL6 target genes, killed DLBCL cells and caused apoptosis as well as cell cycle arrest. In animal models, WK500B inhibited germinal centre (GC) formation and DLBCL tumor growth without toxic and side effects. Moreover, WK500B showed favourable pharmacokinetics and presented superior druggability compared to other BCL6 inhibitors. Conclusions and Implications: WK500B showed strong efficacy and favourable pharmacokinetics and presented superior druggability compared to other BCL6 inhibitors. So, WK500B is a promising candidate that could be developed as an effective orally available therapeutic agent for DLBCL.